Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This therapeutic regimen, evaluated by the International Brain Research Foundation, is a multi-component combination therapy for the treatment and prevention of COVID-19. It consists of the antimalarial drug hydroxychloroquine, the antibiotic azithromycin, and a suite of dietary supplements including elemental zinc, vitamin C, vitamin D3, n-acetylcysteine, elderberry, and quercetin. The regimen was designed to leverage the hypothesized antiviral and immunomodulatory effects of hydroxychloroquine and azithromycin, alongside the immune-supporting and antioxidant properties of the supplements. Specifically, zinc was included for its potential to inhibit viral replication, while quercetin was intended to act as a zinc ionophore. The regimen was studied in a Phase 1 clinical trial to assess safety and efficacy in reducing the severity of COVID-19 symptoms and preventing infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxychloroquine + azithromycin + zinc + vitamin C + vitamin D3 + n-acetylcysteine + elderberry + quercetin.